help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abdel el Motal, S. M.
Right arrow Articles by Sharp, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abdel el Motal, S. M.
Right arrow Articles by Sharp, G. W.

Endocrinology, Vol 116, 2337-2340, Copyright © 1985 by Endocrine Society

ARTICLES

Inhibition of glucose-induced insulin release by xylazine

SM Abdel el Motal and GW Sharp

The effects of xylazine, a sedative that is extensively used in veterinary medicine, on glucose-stimulated insulin release have been studied using isolated perifused rat pancreatic islets. Xylazine had no effect on insulin release under basal conditions. Glucose-stimulated insulin release was inhibited in a concentration-dependent manner over the range of 10(-9)-10(-6) M. Maximum inhibition even with 10(-5) M xylazine was around 80%, which suggested that xylazine is only a partial agonist at its receptor. The inhibitory effect could be completely eliminated by yohimbine, an alpha 2-adrenergic antagonist, and was unaffected by prazosin, an alpha 1-adrenergic antagonist. That xylazine is a partial agonist was verified by the fact that when present in excess, it could stimulate insulin release which had already been inhibited to 100% by epinephrine. It is concluded that xylazine is a potent partial alpha 2-adrenergic agonist and that this mechanism is responsible, at least in part, for the hyperglycemia and insulinopenia associated with its use.


This article has been cited by other articles:


Home page
 JNMHome page
B. J. Fueger, J. Czernin, I. Hildebrandt, C. Tran, B. S. Halpern, D. Stout, M. E. Phelps, and W. A. Weber
Impact of Animal Handling on the Results of 18F-FDG PET Studies in Mice
J. Nucl. Med., June 1, 2006; 47(6): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K.-H. Lee, B.-H. Ko, J.-Y. Paik, K.-H. Jung, Y. S. Choe, Y. Choi, and B.-T. Kim
Effects of Anesthetic Agents and Fasting Duration on 18F-FDG Biodistribution and Insulin Levels in Tumor-Bearing Mice
J. Nucl. Med., September 1, 2005; 46(9): 1531 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Toyama, M. Ichise, J.-S. Liow, K. J. Modell, D. C. Vines, T. Esaki, M. Cook, J. Seidel, L. Sokoloff, M. V. Green, et al.
Absolute Quantification of Regional Cerebral Glucose Utilization in Mice by 18F-FDG Small Animal PET Scanning and 2-14C-DG Autoradiography
J. Nucl. Med., August 1, 2004; 45(8): 1398 - 1405.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1985 by The Endocrine Society